Association Between COVID-19 and UTIs Caused by ESBL Organism in Infants

Renal Insufficiency Clinical Trial

— ABCUCEOI  

Official title:

Clinical, Laboratory, and Radiological Characteristics of Urinary Tract Infections in Infants With COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05630326
• Other study ID #: MRC-01-22-158
• Status: Completed
• Start date: March 1, 2023
• Est. completion date: July 20, 2023

Study information

• Verified date: April 2022
• Source: Hamad Medical Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Urinary tract infections (UTIs) in infants and young children are one of the most common bacterial infections, usually febrile illness without source, frequently due to Enterobacteriaceae, mainly Escherichia coli.

Multidrug-resistant organisms including extended-spectrum beta-lactamase (ESBL) producing bacteria are becoming more prevalent. Due to the risk factors of ESBL-producing organisms in community-acquired (CA)-UTIs in infants in QATAR and Arab countries are still not studied because of the limited therapeutic options. hence, the importance of this study is to get knowledge about how to decrease the rapidly increasing in ESBL- producing bacteria, in infants, and to use antibiotics in a suitable guideline.so, The aim of this retrospective case-control study is to determine the clinical manifestations, and investigations of urinary tract infections among infants and the association with COVID-19 infection, in pediatric emergency centers at Hamad General Hospital - Qatar. From 1st January 2015 till 1st January 2022.

Description:

In this retrospective, case-control study investigators will include all infants (0-1 year) with UTIs who were treated at Hamad General Hospital, pediatric division- PEC Doha, Qatar, using the electronic medical records from 1st January 2015 till January 1st, 2022, diagnosed by a positive urine culture. Investigators will look for the clinical manifestations, radiological and laboratory findings, renal scarring, ESBL-organisms, prevalence, median age, gender, and ethnic background. Participants are divided into two groups: early infancy and late infancy, ESBL UTIs and non-ESBL UTIs, and upper UTIs and lower UTIs. Finally, UTIs ESBL with COVID-19 and without COVID_19.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5600
• Est. completion date: July 20, 2023
• Est. primary completion date: July 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 1 Year

Eligibility

Inclusion Criteria:

• All infants with UTIs who had been treated

Exclusion Criteria:

• Patient with a mixed urine culture.

Related Conditions & MeSH terms

• COVID-19
• Renal Insufficiency

Intervention

Other:
• comparing, prevalence
Comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
• assessment
comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
• association
comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
• evaluation
comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19

Locations

Country	Name	City	State
Qatar	Hamad Medical Corporation	Doha

Sponsors (1)

Lead Sponsor	Collaborator
Hamad Medical Corporation

Country where clinical trial is conducted

Qatar, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment risk factors , prevalence, and the relation between ESBL UTI and COVID-19 infection of all infants with ESBL- UTIs		1year